Analysis
Swiss biotech Nouscom raised $135 million (€120 million) in an oversubscribed Series D round co-led by M Ventures -- the venture arm of Germany's Merck KGaA -- and Revelation Partners, the company said Monday, according to Startup Ticker. New investors Angelini Industries, the European Investment Bank (through its Aurea co-investment facility with Angelini Ventures), and Neva SGR of the Intesa Sanpaolo Group joined a syndicate of existing backers that includes 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, CDP Venture Capital, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, and XGEN Ventures.
What the money funds
The proceeds back a single, global, registration-enabling trial of NOUS-209, Nouscom's lead candidate, for cancer interception in Lynch syndrome carriers -- an inherited condition that raises lifetime cancer risk to as much as 50% for colorectal and endometrial cancer, versus roughly 1-2% in the general population, and up to 25% for urothelial cancer. NOUS-209 is an off-the-shelf neoantigen immunotherapy that uses two proprietary viral vectors to deliver 209 shared frameshift peptide neoantigens -- markers found on tumors with mismatch repair deficiency and microsatellite instability but absent from healthy cells -- aiming to train the immune system to clear cancerous and precancerous cells before a tumor forms. The FDA has granted the program Fast Track designation, and Phase 1b/2 data presented at this month's ESMO Congress showed every evaluable Lynch syndrome carrier remained free of advanced adenomas and colorectal cancer after one year (43 patients) and two years (17 patients), with responses strengthening after annual re-treatment.
“Nouscom is separately running Phase 2 trials combining NOUS-209 with Keytruda (pembrolizumab), the checkpoint inhibitor sold by the US drugmaker Merck & Co.”
Nouscom is separately running Phase 2 trials combining NOUS-209 with Keytruda (pembrolizumab), the checkpoint inhibitor sold by the US drugmaker Merck & Co. -- an unrelated company to Series D co-lead M Ventures' parent, Germany's Merck KGaA -- in anti-PD-1-refractory metastatic colorectal cancer, giving the company a nearer-term commercial path if the longer cancer-interception trial takes years to read out. The company's approach sits in a cancer-vaccine field increasingly populated by much larger players: Moderna and Merck's mRNA-4157/V940 melanoma vaccine and BioNTech's autogene cevumeran, developed with Genentech, are both further along in later-stage trials, but target treatment of existing tumors rather than prevention in genetically defined high-risk populations -- a narrower, earlier-intervention bet than either program is making.
What the headline misses: a cancer-prevention vaccine for a hereditary condition serves a comparatively small patient population by cancer-drug standards, and running a single global registration trial for an endpoint built around precancerous lesion regression is regulatory terrain with few precedents. M Ventures' Hakan Goker called the combination of maturing clinical data and a regulatory-aligned path rare for a private biotech, which is itself an acknowledgment that most candidates in this space never get this far.
CEO Marina Udier said the financing and ESMO data move Nouscom closer to stopping cancer before it starts, a framing consistent with the sector's broader shift toward interception rather than late-stage treatment -- a shift that only works commercially if payers agree a one-time prevention vaccine is worth pricing like a chronic therapy.
